Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations research located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://leonardy042pdm6.livebloggs.com/profile